Compare Stocks

Endeavor Group Holdings, Inc. operates as a sports and entertainment company in the United States, the United Kingdom, and internationally. It operates through four segments: Owned Sports Properties; Events, Experiences & Rights; Representation; and Sports Data & Technology. The Owned Sports Properties segment operates a portfolio of sports properties, including Ultimate Fighting Championship, World Wrestling Entertainment, Inc., Professional Bull Rider, and Euroleague. The Events, Experiences & Rights segment provides services to live events, including sporting events, fashion, art fairs and music, culinary, lifestyle festivals, and major attractions. This segment also distributes sports programming; and operates events on behalf of third parties. The Representation segment offers services to talent across entertainment, sports, and fashion, such as actors, directors, writers, athletes, models, musicians, and other artists in various mediums. This segment provides brand strategy, marketing, advertising, public relations, analytics, digital, activation, and experiential services to corporate and other clients; intellectual property licensing services to a portfolio of entertainment, sports, and consumer product brands, including clients' licensing logos, trade names, and trademarks representation. The Sports Data & Technology segment delivers live streaming and data feeds for sports events to sportsbooks, rightsholders, and media partners, as well as on-demand virtual sports products and front-end solutions, including the UFC Event Centre. This segment also specializes in betting engine products, services and technology, and bet processing, as well as trading, pricing, and risk management tools; player account and wallet solutions; front-end user experiences and user interfaces; and content offerings, such as BetBuilder, DonBest pricing feeds, and a sports content aggregation platform. The company was founded in 1898 and is based in Beverly Hills, California.

GoGold Resources Inc. engages in the exploration, development, and production of gold and silver in Mexico. The company holds 100 % interest in the Parral Tailings project, which covers an area of 141 hectares located in the state of Chihuahua, Mexico. It also holds 100% interest in the Los Ricos properties, which includes Los Ricos South and Los Ricos North projects, that covers 42 concessions with an area of approximately 22,000 hectares situated in the Jalisco State, Mexico. The company was incorporated in 2008 and is headquartered in Halifax, Canada.

NeuStar, Inc. is a global information services provider. The Company's cloud-based platforms and differentiated data sets offer informative, real-time analytics, which enable clients to make actionable, data-driven decisions. It provides chief marketing officers a suite of services to plan their media spends, identify and locate desired customers, invest in marketing campaigns, deliver relevant offers and measure the performance of these activities. Security professionals use the Company's solutions to maximize Web performance and protect against malicious attacks. It enables the exchange of essential operating information across multiple carriers to provision and manage services, assisting clients with order processing and routing of customer inquiries. The Company's services include marketing services, security services, data services and number portability administration center (NPAC) services.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.